Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cephalon Provigil Has 28% Awareness Among Primary Care Physicians

Executive Summary

Cephalon will step up its efforts to target primary care physicians in an effort to raise awareness about the sleep disorder agent Provigil (modafinil)

You may also be interested in...



Cephalon Stays Focused On Provigil; ADHD Launch Will Boost Sales Force 40%

Cephalon expects to increase its sales force by 40% in the second half of 2005 in order to support an upcoming launch of Provigil (modafinil) for pediatric attention deficit hyperactivity disorder

Cephalon Stays Focused On Provigil; ADHD Launch Will Boost Sales Force 40%

Cephalon expects to increase its sales force by 40% in the second half of 2005 in order to support an upcoming launch of Provigil (modafinil) for pediatric attention deficit hyperactivity disorder

Cephalon Marketing Under Investigation By Philadelphia U.S. Attorney

The Philadelphia U.S. Attorney's investigation into Cephalon's marketing practices covers the entire commercial life of Provigil

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS043748

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel